Table 3.
Hazard ratios (HRs)a of HBeAg loss among North American children and adults with CHB by participant characteristics.
| Unadj. HR (95% CI) | Adj. HR (95% CI)b N=532 |
Adj. HR (95% CI)c | |
|---|---|---|---|
| Sex (ref=Female) | n=577, P=0.01 | P=0.04 | |
| Male | 1.49 (1.10–2.02) | 1.44 (1.02–2.02) | |
| Age group, years (ref=0.5–10) | n=577, P<0.01 | P<0.01 | |
| >10 – 20 | 1.89 (0.86–4.19) | 1.75 (0.71–4.27) | |
| >20 – 30 | 2.56 (1.23–5.34) | 2.64 (1.14–6.10) | |
| >30 – 40 | 2.95 (1.43–6.10) | 3.29 (1.44–7.49) | |
| >40 – 50 | 4.36 (2.10–9.09) | 4.33 (1.87–10.03) | |
| >50 | 4.49 (2.11–9.55) | 3.94 (1.62–9.60) | |
| Pregnant (ref=no/unknown/NA) | n=577, P=0.54 | P=0.45 | |
| Yes, 24 weeks prior | 1.43 (0.46–4.50) | 1.58 (0.48–5.15) | |
| Race (ref= Asian) | n=561d, P<0.01 | n=556, P<0.01 | |
| Black | 1.93 (1.07–3.51) | 1.90 (1.01–3.57) | |
| White | 2.16 (1.28–3.63) | 2.32 (1.32–4.07) | |
| Genotype (ref=C) | n=536d, P<0.0001 | P<0.01 | |
| A1 | 1.64 (0.66–4.09) | 1.52 (0.61–3.83) | |
| A2 | 3.93 (2.32–6.68) | 2.98 (1.67–5.30) | |
| B | 1.33 (0.94–1.89) | 1.46 (1.02–2.09) | |
| D | 0.69 (0.33–1.44) | 0.95 (0.44–2.07) | |
| E | 1.03 (0.25–4.21) | 1.34 (0.33–5.56) | |
| BCP/PC mutation (ref=wildtype) | n=440, P<0.0001 | n=416, P<0.0001 | |
| BCP only | 2.19 (1.43–3.34) | 2.34 (1.46–3.75) | |
| PC with or without BCP | 4.91 (2.94–8.22) | 5.89 (3.34–10.39) | |
| Phenotype (ref= HBeAg+ immune active) | n=538, P<0.0001 | n=508, P<0.0001 | |
| Immune tolerant | 0.55 (0.30–.99) | 0.58 (0.31–1.08) | |
| HBeAg+ indeterminant | 4.59 (3.10–7.01) | 5.74 (3.63–9.08) | |
| HBV treatment (ref=No) | n=577, P=0.53 | P=0.16 | |
| Yes ≥24wks in past 36 weeks | 1.11 (0.80–1.53) | 0.78 (0.55–1.10) | |
| ALT flare (≥10xULN) (ref=no) | n=572, P<0.0001 | P<0.0001 | |
| Yes, 24 weeks prior | 4.47 (2.76–7.23) | 4.40 (2.65–7.31) | |
| Serum HBsAg (log10 IU/mL) | n=510, P<0.0001 | n=484, P<0.0001 | |
| 24 weeks prior | 0.74 (0.66–0.84) | 0.67 (0.58–0.77) | |
| Serum HBeAg (log10 IU/mL) | n=512, P<0.0001 | n=486, P<0.0001 | |
| 24 weeks prior | 0.52 (0.46–0.59) | 0.46 (0.39–0.53) | |
| HBV DNA (log10 IU/mL) | n=567, P<0.0001 | n=527, P<0.0001 | |
| 24 weeks prior | 0.90 (0.85–0.94) | 0.73 (0.67–0.80) |
Abbreviations: ALT, Alanine aminotransferase; BCP, basal core promoter; CHB, chronic Hepatitis B virus; PC, Pre-core.
The ratio of the rate at which participants experience HBeAg loss where a faster rate suggests a shorter time of HBeAg positivity. Thus, a value >1 indicates less time to HBeAg loss.
Estimate are from one multivariable model that includes sex, age group, pregnancy, genotype, treatment and ALT flare.
Each estimate is from a unique model with adjustment for sex, age group, pregnancy, genotype, treatment and ALT flare with two exceptions; race is not adjusted for genotype; phenotype is not adjusted for ALT flare.
Does not include those in “other/mixed” race (n=16), “other” genotype categories (n=1).